XRCC1 Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid leukemia

被引:20
作者
Banescu, Claudia [1 ]
Duicu, Carmen [2 ]
Trifa, Adrian P. [4 ]
Dobreanu, Minodora [3 ]
机构
[1] Univ Med & Pharm Tirgu Mures, Dept Med Genet, Targu Mures 540139, Romania
[2] Univ Med & Pharm Tirgu Mures, Dept Pediat, Targu Mures 540139, Romania
[3] Univ Med & Pharm Tirgu Mures, Dept Clin Biochem & Lab, Targu Mures 540139, Romania
[4] Iuliu Hatieganu Univ Med & Pharm, Dept Med Genet, Cluj Napoca, Romania
关键词
RCC1; gene; genetic polymorphisms; myeloid leukemia; DNA-REPAIR GENES; ACUTE LYMPHOBLASTIC-LEUKEMIA; BASE EXCISION-REPAIR; WORLD-HEALTH-ORGANIZATION; CANCER-RISK; BREAST-CANCER; XPD; LYMPHOMA; METAANALYSIS; CLASSIFICATION;
D O I
10.3109/10428194.2013.802781
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the base excision repair pathway, the predominant DNA damage repair mechanism, X-ray repair cross-complementing group 1 (XRCC1) gene, has a crucial role. Defects in repair pathways are involved in cancer pathogenesis. Therefore, DNA repair genes might be involved in acute myeloid leukemia (AML) susceptibility. Our study aimed to evaluate the relationship between XRCC1 Arg194Trp, Arg280His and Arg399Gln polymorphisms and AML. Sixty-nine patients with AML and 147 healthy controls were included. We noted a significant association between the polymorphisms Arg194Trp (p-value = 0.0002 for Trp allele) and Arg399Gln (p-value = 0.003 for Gln allele) and AML risk. There was a significantly better overall survival among patients with AML with wild-type homozygous compared to those with at least one variant allele in the case of Arg194Trp (p-value = 0.0019) and Arg399Gln polymorphisms (p-value = 0.049). Our study suggests the involvement of XRCC1 Arg194Trp and Arg399Gln polymorphisms in the genetic predisposition to AML. These two XRCC1 polymorphisms could also be prognostic markers in AML as they were significantly associated with overall survival.
引用
收藏
页码:365 / 370
页数:6
相关论文
共 41 条
[1]   Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy [J].
Allan, JM ;
Smith, AG ;
Wheatley, K ;
Hills, RK ;
Travis, LB ;
Hill, DA ;
Swirsky, DM ;
Morgan, GJ ;
Wild, CP .
BLOOD, 2004, 104 (13) :3872-3877
[2]   The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens [J].
Artac, Mehmet ;
Bozcuk, Hakan ;
Pehlivan, Sacide ;
Akcan, Songuel ;
Pehlivan, Mustafa ;
Sever, Tugce ;
Ozdogan, Mustafa ;
Savas, Burhan .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (06) :803-809
[3]   The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia [J].
Barragan, Eva ;
Collado, Maria ;
Cervera, Jose ;
Martin, Guillermo ;
Bolufer, Pascual ;
Roman, Jose ;
Sanz, Miguel A. .
LEUKEMIA RESEARCH, 2007, 31 (07) :947-953
[4]   DNA repair gene XPD and XRCC1 polymorphisms and the risk of childhood acute lymphoblastic leukemia [J].
Batar, Bahadir ;
Guven, Mehmet ;
Baris, Safa ;
Celkan, Tiraje ;
Yildiz, Inci .
LEUKEMIA RESEARCH, 2009, 33 (06) :759-763
[5]   XRCC1 and DNA strand break repair [J].
Caldecott, KW .
DNA REPAIR, 2003, 2 (09) :955-969
[6]   Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer [J].
Chacko, P ;
Rajan, B ;
Joseph, T ;
Mathew, BS ;
Pillai, MR .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 89 (01) :15-21
[7]  
Chen PL, 2010, MOL VIS, V16, P991
[8]   Targeting DNA repair pathways in AML [J].
D'Andrea, Alan D. .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2010, 23 (04) :469-473
[9]  
Deligezer U, 2007, ANTICANCER RES, V27, P2453
[10]  
Dufloth RM, 2005, GENET MOL RES, V4, P771